Calidi Biotherapeutics Inc. Featured for Breakthrough Genetic Medicine Platform in Cancer Treatment
TL;DR
Calidi Biotherapeutics' innovative platform offers a competitive edge in oncology by targeting tumors with engineered viruses, potentially revolutionizing cancer treatment.
Calidi Biotherapeutics utilizes engineered viruses delivered via stem cells to precisely target and treat cancer tumors, showcasing a methodical approach to oncology.
Calidi Biotherapeutics' technology promises a brighter future by offering a novel solution to combat cancer, aiming to improve millions of lives globally.
Discover how Calidi Biotherapeutics is pioneering a dual approach to treat cancer with engineered viruses and stem cells, a groundbreaking advancement in medicine.
Found this article helpful?
Share it with your network and spread the knowledge!
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has recently been featured in an editorial by NetworkNewsWire, showcasing its groundbreaking precision genetic medicine platform. This platform is designed to target both primary and metastatic cancer tumors through the use of engineered viruses, presenting a promising avenue in the fight against cancer. With projections indicating that global cancer diagnoses could reach 35 million annually by 2050, Calidi's technology is timely and could address significant unmet needs in oncology.
The company's approach focuses on delivering potent genetic therapies directly to cancer sites, leveraging engineered viruses to attack tumors. This method not only represents a novel strategy in cancer treatment but also has the potential to disrupt traditional oncology therapies by offering a more targeted and possibly less invasive option. Calidi Biotherapeutics is at the forefront of developing solutions that could significantly improve patient outcomes, especially in cases of high-grade gliomas and solid tumors.
Calidi's clinical-stage immuno-oncology company is pioneering the use of proprietary stem cell-based platforms. These platforms are capable of carrying payloads of oncolytic viruses, which are then used to treat various oncology indications. The company's off-the-shelf, universal cell-based delivery systems are engineered to protect, amplify, and potentiate oncolytic viruses, aiming to enhance efficacy and improve patient safety. Additionally, Calidi's preclinical enveloped virotherapies are being developed to target disseminated solid tumors, offering a dual approach that could treat or even prevent metastatic disease.
Headquartered in San Diego, California, Calidi Biotherapeutics is making strides in the field of genetic medicine and oncology. For more information on their innovative platforms and research, visit their website at https://www.calidibio.com. The company's progress and updates are also available in their newsroom at https://ibn.fm/CLDI.
Curated from InvestorBrandNetwork (IBN)
